XML 53 R32.htm IDEA: XBRL DOCUMENT
v3.3.1.900

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Oct. 31, 2015 | Jun. 18, 2013
Significant Accounting Policies [Line Items] |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 19,778,424 | 18,850,724 | 10,675,304 |  |
Revenues, Total | $ 4,364 | $ 3,523 | $ 0 |  |
Brazil [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Percentage of Adult Gaucher Patients Treated with Uplyso | 10.00% |  |  |  |
Subsidiaries [Member] | Sales Revenue, Goods, Net [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Revenues, Total | $ 4,000 |  |  |  |
Brazil Agreement [Member] | Subsidiaries [Member] | Fiocruz [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Purchase Amount To Be Satisfied To Receive Entitled Rights |  |  |  |  | $ 280,000
Agent Fee, Percentage Of Net Proceeds | 5.00% |  |  |  |
Pfizer Agreement [Member] | Pfizer Incorporation [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 60.00% |  |  |  |
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 40.00% |  |  |  |
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member] |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  |  |  | 100.00% |

X
- Definition The Company will pay a fee equal to percentage of the net proceeds generated in Brazil to its agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between the agent and the Company. + References No definition available. + Details
Name: | plx_AgentFeePercentageOfNetProceeds
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the percentage of adult Gaucher patients treated with Uplyso. + References No definition available. + Details
Name: | plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements. + References No definition available. + Details
Name: | plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=us-gaap_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=plx_FiocruzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |